FindTrial
Sign In

Study on patients with advanced liver cancer who have received chemotherapy and have undergone liver transplant

Living donor liver transplant in advanced hepatocellular carcinoma (HCC) down staged with systemic therapy with or without locoregional therapy (LRT) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/03/064473
Enrollment
220
Registered
2024-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C220- Liver cell carcinoma

Interventions

Intervention1: NIL as this is observational study: NIL as this is observational study

Sponsors

Nanavati Max Institute of Liver Intestine Pancreas Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: HCC downstaged with systemic therapy with or without locoregional therapy to within UCSF criteria

Exclusion criteria

Exclusion criteria: 1. Extrahepatic metastasis 2. Poor performance status

Design outcomes

Primary

MeasureTime frame
1.Overall survival at 1 year post transplant and end of study- Transplant Benefit (comparison between the 4 groups) 2. Recurrence free survival at 1 year post transplant and end of study (Group 1, 4) 3. Recurrence rate at 1 year post transplant and end of study (Group 1, 4) Timepoint: 3 years—

Secondary

MeasureTime frame
1. Rejection rate over 1 year (Group 1, 4) 2. Surgery related complications â?? bleeding, wound healing, biliary complications, infections (Group 1, 4) 3. Duration of stable disease before transplant â?? correlation with recurrence (Group 1, 4) 4. Tumour characteristics on explant histology â?? correlation with recurrence (Group 1, 4) 5. Pre Transplant Response to Systemic therapy â?? partial or complete - correlation with recurrence- Radiological & biochemical (Group 1, 4) 6. Recurrent disease â?? intrahepatic or extrahepatic (Group 1, 4)Timepoint: 3 years—

Countries

India

Contacts

Public ContactDr Alisha Chaubal

Nanavati Max Super Speciality Hospital

alishachaubal@gmail.com9967321108

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026